Afinitor everolimus: Additional Phase III data

Novartis markets everolimus as Afinitor in the U.S. and EU to treat advanced renal cell carcinoma (RCC), breast cancer, neuroendocrine tumors of pancreatic origin and renal angiomyolipomas, as Certica...